<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">570</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2021-20-4-154-167</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Giant cell angioblastoma</article-title><trans-title-group xml:lang="ru"><trans-title>Гигантоклеточная ангиобластома</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khachatryan</surname><given-names>L. A.</given-names></name><name xml:lang="ru"><surname>Хачатрян</surname><given-names>Л. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>cand. med. sci., Head of Box Department of Hematology/Oncology,</p><p>1 Samory Mashela St., Moscow 117997</p></bio><bio xml:lang="ru"><p>канд. мед. наук, заведующая боксированным отделением гематологии/онкологии,</p><p>117997, Москва, ул. Саморы Машела, 1</p></bio><email>lili.2510@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kletskaya</surname><given-names>I. S.</given-names></name><name xml:lang="ru"><surname>Клецкая</surname><given-names>И. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Samory Mashela St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997, Москва, ул. Саморы Машела, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tereshchenko</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Терещенко</surname><given-names>Г. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Samory Mashela St., Moscow 117997</p></bio><bio xml:lang="ru"><p>117997, Москва, ул. Саморы Машела, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-12-22" publication-format="electronic"><day>22</day><month>12</month><year>2021</year></pub-date><volume>20</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>154</fpage><lpage>167</lpage><history><date date-type="received" iso-8601-date="2021-12-21"><day>21</day><month>12</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-12-21"><day>21</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/570">https://hemoncim.com/jour/article/view/570</self-uri><abstract xml:lang="en"><p>Giant cell angioblastoma is an extremely rare tumor of vascular origin, described at the end of the 20th century. It belongs to tumors with intermediate malignant potential and is characterized by locally infiltrative growth. The tumor doesn’t have any clear distinctive clinical characteristics. The diagnosis is established on the basis of histological examination. Two main treatment options for this pathology are discussed in the literature: radical removal of the tumor and therapy with low doses of interferon alpha. As a rule, this is a combination treatment. This article describes our own clinical case. The patient’s parents gave their consent to the use of their child’s data, including photographs, for research purposes and in publications. Interest is in the rarity of the disease and the features of the clinical characteristics of this case, specifically the extremely unfavorable localization in the oropharynx region and, accordingly, the impossibility of carrying out not only a radical removal of the tumor, but also its resection. The high probability of developing irreversible neurological complications in this age group associated with interferon alpha therapy questioned the possibility of its use. For the first time in this histological variant of a vascular tumor, chemotherapy was applied, including metronomic therapy with cyclophosphamide and vinblastine in combination with a liposomal form of doxorubicin. After 8 courses of chemotherapy, a complete clinical response was obtained with the restoration of the patency of the respiratory and digestive tracts. The observation period at the time writing of this article was 36 months. </p></abstract><trans-abstract xml:lang="ru"><p>Гигантоклеточная ангиобластома (ГКАБ) – это крайне редкая опухоль сосудистого генеза, описанная в конце ХХ века. Она относится к образованиям с промежуточным злокачественным потенциалом и характеризуется локально инфильтративным ростом. Опухоль не имеет каких-либо четких отличительных клинических характеристик. Диагноз устанавливается исключительно на основании гистологического исследования. В литературе обсуждаются 2 основные опции лечения данной патологии: радикальное удаление опухоли и терапия низкими дозами интерферона альфа. Как правило, это комбинированное лечение. В данной статье приводится описание собственного клинического случая. Родители пациента дали согласие на использование информации, в том числе фотографий ребенка, в научных исследованиях и публикациях. Интерес представляют как редкость заболевания, так и особенности клинических характеристик данного случая, а именно крайне неблагоприятная локализация в области ротоглотки и соответственно невозможность проведения не только радикального удаления опухоли, но и ее резекции. Высокая вероятность развития необратимых неврологических осложнений в этой возрастной группе, связанных с терапией интерфероном альфа, ставила под сомнение возможность его применения. Впервые при данном гистологическом варианте сосудистой опухоли была применена химиотерапия, включающая метрономную терапию циклофосфаном и винбластином в комбинации с липосомальной формой доксорубицина. После 8 курсов химиотерапии был получен полный клинический ответ с восстановлением проходимости дыхательных и пищеварительных путей. Период наблюдения к моменту написания статьи составил 36 мес. </p></trans-abstract><kwd-group xml:lang="en"><kwd>vascular tumor</kwd><kwd>giant cell angioblastoma</kwd><kwd>liposomal form of doxorubicin</kwd><kwd>interferon alpha</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сосудистая опухоль</kwd><kwd>гигантоклеточная ангиобластома</kwd><kwd>липосомальная форма доксорубицина</kwd><kwd>интерферон альфа</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Gonzalez-Crussi F., Chou P., Crawford S.E. Congenital, infiltrating giant-cell angioblastoma. A new entity? Am J Surg Pathol 1991; 15 (2): 175–183.</mixed-citation><mixed-citation xml:lang="ru">Gonzalez-Crussi F., Chou P., Crawford S.E. Congenital, infiltrating giant-cell angioblastoma. A new entity? Am J Surg Pathol 1991; 15 (2): 175–183.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. WHO Classification of Tumors of Soft Tissue and bone IARC 2020 3. ISSVA Classification of Vascular Anomalies ©2018 International Society for the Study of Vascular Anomalies Available at: http://issva.org/classification. Accessed 27.03.2021.</mixed-citation><mixed-citation xml:lang="ru">WHO Classification of Tumors of Soft Tissue and bone IARC 2020 3. ISSVA Classification of Vascular Anomalies ©2018 International Society for the Study of Vascular Anomalies Available at: http://issva.org/classification. Accessed 27.03.2021.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">4. Wechsler J. Pathologie cutanée tumoral. 2nd edition. 2016. P. 247.</mixed-citation><mixed-citation xml:lang="ru">Wechsler J. Pathologie cutanée tumoral. 2nd edition. 2016. P. 247.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">5. Vargas S.O., Perez-Atayde A.R., González-Crussi F., Kozakewich H.P. Giant cell angioblastoma. Three additional occurrences of a distinct pathlogic entity. Am J Syrg Pathol 2001; 25 (2): 185–96.</mixed-citation><mixed-citation xml:lang="ru">Vargas S.O., Perez-Atayde A.R., González-Crussi F., Kozakewich H.P. Giant cell angioblastoma. Three additional occurrences of a distinct pathlogic entity. Am J Syrg Pathol 2001; 25 (2): 185–96.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">6. Mao R.J., Li Q.M., Guo Y.M., Li W.Q., Fan C.S., Zhu X.Z. Clinicopathologic study of giant cell angioblastoma. Zhonghua Bing Li Xue Za Zhi 2011; 39 (11): 752–6.</mixed-citation><mixed-citation xml:lang="ru">Mao R.J., Li Q.M., Guo Y.M., Li W.Q., Fan C.S., Zhu X.Z. Clinicopathologic study of giant cell angioblastoma. Zhonghua Bing Li Xue Za Zhi 2011; 39 (11): 752–6.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">7. Mao R.J., Jiang Z.M., Zhang H.Z., Zhu X.Z., Zhang Q.L. Clinical and pathological characteristics of giant cell angioblastoma: a case report. Diagn Pathol 2012; 7: 113.</mixed-citation><mixed-citation xml:lang="ru">Mao R.J., Jiang Z.M., Zhang H.Z., Zhu X.Z., Zhang Q.L. Clinical and pathological characteristics of giant cell angioblastoma: a case report. Diagn Pathol 2012; 7: 113.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">8. Marler J.J., Rubin J.B., Trede N.S., Connors S., Grier H., Upton J., et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 2002; 109 (2): Е37.</mixed-citation><mixed-citation xml:lang="ru">Marler J.J., Rubin J.B., Trede N.S., Connors S., Grier H., Upton J., et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 2002; 109 (2): Е37.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">9. Yu L., Weng Lao I., Wang J. Giant cell angioblastoma of bone: four new cases provide further evidence of its distinct clinical and histopathological characteristics. Virchows Arch 2015; 467 (1): 95–103.</mixed-citation><mixed-citation xml:lang="ru">Yu L., Weng Lao I., Wang J. Giant cell angioblastoma of bone: four new cases provide further evidence of its distinct clinical and histopathological characteristics. Virchows Arch 2015; 467 (1): 95–103.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">10. Crivell-Ochsner S., Bode-Lesniewska B., NussbaumerOchsner Y., Fuchs B. Giant cell angioblastoma in an adult: a unique presentation. Rare Tumors 2013; 5 (3): e27.</mixed-citation><mixed-citation xml:lang="ru">Crivell-Ochsner S., Bode-Lesniewska B., NussbaumerOchsner Y., Fuchs B. Giant cell angioblastoma in an adult: a unique presentation. Rare Tumors 2013; 5 (3): e27.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">11. Ma Y., Du R., Zheng J., Ma R., Xiao X., Chen L., et al Giant cell angioblastoma in the femur: three additional pediatric cases provide more data of its clinicopathological features. Int J Clin Exp Pathol 2016; 9 (6): 6334–41.</mixed-citation><mixed-citation xml:lang="ru">Ma Y., Du R., Zheng J., Ma R., Xiao X., Chen L., et al Giant cell angioblastoma in the femur: three additional pediatric cases provide more data of its clinicopathological features. Int J Clin Exp Pathol 2016; 9 (6): 6334–41.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">12. Zhang R.-Y., Miao X.-M., Gao Z., Tian H.-S., Chen S. Multiple bone giant cell angioblastomas in children: a case report and literature review. Int J Clin Exp Med 2018; 11 (11): 12745–51.</mixed-citation><mixed-citation xml:lang="ru">Zhang R.-Y., Miao X.-M., Gao Z., Tian H.-S., Chen S. Multiple bone giant cell angioblastomas in children: a case report and literature review. Int J Clin Exp Med 2018; 11 (11): 12745–51.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">13. Caraglia M., Marra M., Tagliaferri P., Lamberts S.W., Zappavigna S., Misso G., et al. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets 2009; 9 (5): 690–704.</mixed-citation><mixed-citation xml:lang="ru">Caraglia M., Marra M., Tagliaferri P., Lamberts S.W., Zappavigna S., Misso G., et al. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets 2009; 9 (5): 690–704.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">14. Пейдж К., Кертис М., Уокер М., Хоффман Б. Фармакология. Клинический подход. Пер. с англ.; под ред. Б.К. Романова. М.: Логосфера; 2012. 744 с.</mixed-citation><mixed-citation xml:lang="ru">Пейдж К., Кертис М., Уокер М., Хоффман Б. Фармакология. Клинический подход. Пер. с англ.; под ред. Б.К. Романова. М.: Логосфера; 2012. 744 с.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">15. Delmontte N., Curti C., Motana M., Crozet M., Vanelle P., Gensollen S. Mise au point sur traitement de lhémangiome du nourrisson par beta-bloquant. Therapies 2012; 67 (3): 257–65.</mixed-citation><mixed-citation xml:lang="ru">Delmontte N., Curti C., Motana M., Crozet M., Vanelle P., Gensollen S. Mise au point sur traitement de lhémangiome du nourrisson par beta-bloquant. Therapies 2012; 67 (3): 257–65.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">16. Folkman J., Mulliken J.B., Ezekowitz R.B. Antiangiogenic therapy of haemangiomas with interferon A. The clinical applications of the interferons. London, England: Chapman Hall Medical; 1997. Рр. 255–265.</mixed-citation><mixed-citation xml:lang="ru">Folkman J., Mulliken J.B., Ezekowitz R.B. Antiangiogenic therapy of haemangiomas with interferon A. The clinical applications of the interferons. London, England: Chapman Hall Medical; 1997. Рр. 255–265.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">17. Fleischmann W., Fleischmann C. Mechanism of interferons antitumor actions. In: Baron S., Coppenhaver D., Dianzini F., eds. Interferon: Principles and Medical Applications. Galveston, TX: University of Texas Medical Branch; 1992. Рр. 299–310.</mixed-citation><mixed-citation xml:lang="ru">Fleischmann W., Fleischmann C. Mechanism of interferons antitumor actions. In: Baron S., Coppenhaver D., Dianzini F., eds. Interferon: Principles and Medical Applications. Galveston, TX: University of Texas Medical Branch; 1992. Рр. 299–310.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">18. Brouty-Boye D., Zetter B. Inhibition of cell motility by interferon. Science 1980; 208: 516–8.</mixed-citation><mixed-citation xml:lang="ru">Brouty-Boye D., Zetter B. Inhibition of cell motility by interferon. Science 1980; 208: 516–8.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">19. Stephan D., Weltin D., Chapelon D., Da Silva A., Lugniers C. Angiogénèse: de la physiologie à la thérapeutique. Réanim Urgences 2000; 9: 534–44.</mixed-citation><mixed-citation xml:lang="ru">Stephan D., Weltin D., Chapelon D., Da Silva A., Lugniers C. Angiogénèse: de la physiologie à la thérapeutique. Réanim Urgences 2000; 9: 534–44.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">20. Takahashi K., Mulliken J.B., Kozakewich H.P.W., Rogers R., Folkman J., Ezekowitz R.A.B. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93: 2357–64.</mixed-citation><mixed-citation xml:lang="ru">Takahashi K., Mulliken J.B., Kozakewich H.P.W., Rogers R., Folkman J., Ezekowitz R.A.B. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93: 2357–64.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">21. Presta M., Dell Era P., Miyola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16 (2): 159–78.</mixed-citation><mixed-citation xml:lang="ru">Presta M., Dell Era P., Miyola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16 (2): 159–78.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">22. White C., Sondheimer H.M., Crouch E.C., Wilson H., Fan L.L. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197–200.</mixed-citation><mixed-citation xml:lang="ru">White C., Sondheimer H.M., Crouch E.C., Wilson H., Fan L.L. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 1989; 320: 1197–200.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">23. Katz H.P., Askin J. Multiple hemangioma with trombopenie: an unusual case with comments on steroid therapy. Am J Dis Child 1968; 115 (3): 351–7.</mixed-citation><mixed-citation xml:lang="ru">Katz H.P., Askin J. Multiple hemangioma with trombopenie: an unusual case with comments on steroid therapy. Am J Dis Child 1968; 115 (3): 351–7.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">24. Groopman J.E., Gottlieb M.S., Goodman J., Mitsuyasu R.T., Conant M.A., Prince H., et al. Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100 (5): 671–6.</mixed-citation><mixed-citation xml:lang="ru">Groopman J.E., Gottlieb M.S., Goodman J., Mitsuyasu R.T., Conant M.A., Prince H., et al. Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100 (5): 671–6.</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">25. Orchard P., Smith C.M., Woods W.G., Day D.L., Dehner L.P., Shapiro R. Treatment of haemangioendotheliomas with alfa interferon. Lancet 1989; 2: 565–7.</mixed-citation><mixed-citation xml:lang="ru">Orchard P., Smith C.M., Woods W.G., Day D.L., Dehner L.P., Shapiro R. Treatment of haemangioendotheliomas with alfa interferon. Lancet 1989; 2: 565–7.</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">26. Singh R., Gutman M., Bucana C.D., Sanchez R., Llansa N., Fidler I.J. Interferons alfa and beta down-regulate the eхperssion of basic fiblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 4562–6.</mixed-citation><mixed-citation xml:lang="ru">Singh R., Gutman M., Bucana C.D., Sanchez R., Llansa N., Fidler I.J. Interferons alfa and beta down-regulate the eхperssion of basic fiblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 4562–6.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">27. Ezekowitz R., Mulliken J.B., Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456–63.</mixed-citation><mixed-citation xml:lang="ru">Ezekowitz R., Mulliken J.B., Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456–63.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">28. Herron M.D., Coffin C.M., Vanderhooft S.L. Tufted angiomas: variability of clinical morphology. Pediatr Dermatol 2002; 19 (5): 394–401.</mixed-citation><mixed-citation xml:lang="ru">Herron M.D., Coffin C.M., Vanderhooft S.L. Tufted angiomas: variability of clinical morphology. Pediatr Dermatol 2002; 19 (5): 394–401.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">29. Michaud A.P., Bauman N.M., Burke D.K., Manaligod J.M., Smith R.J.H. Spastic diplegia and other motor disturbances in infants receiving interferon alpha. Laryngoscope 2004; 114: 1231–6.</mixed-citation><mixed-citation xml:lang="ru">Michaud A.P., Bauman N.M., Burke D.K., Manaligod J.M., Smith R.J.H. Spastic diplegia and other motor disturbances in infants receiving interferon alpha. Laryngoscope 2004; 114: 1231–6.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">30. Хачатрян Л.А., Масчан А.А., Орехова Е.В., Новичкова Г.А. Терапия детей с синдромом Казабаха– Мерритт. Педиатрия. Журнал им. Г.Н. Сперанского 2018; 97 (4): 125–34.</mixed-citation><mixed-citation xml:lang="ru">Хачатрян Л.А., Масчан А.А., Орехова Е.В., Новичкова Г.А. Терапия детей с синдромом Казабаха– Мерритт. Педиатрия. Журнал им. Г.Н. Сперанского 2018; 97 (4): 125–34.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
